Care Clinic Sp. z o.o.
- Address
- lock Available on a paid plan
Neurology and Neuroimmunology
At Care Clinic Sp. z o.o. in Katowice, clinical research in nervous system diseases focuses mainly on multiple sclerosis and related conditions, including primary progressive multiple sclerosis and relapsing multiple sclerosis. These studies are designed to assess new treatment options, compare therapeutic effectiveness, and better understand long-term safety in people living with chronic neurological disease.
- Testing therapies for relapsing forms of multiple sclerosis
- Evaluating treatment effectiveness in primary progressive multiple sclerosis
- Studying safety, tolerability, and delivery of ocrelizumab and ublituximab
The site’s work in this area reflects a strong interest in improving disease control and treatment convenience for patients with complex neuroimmunological disorders.
Dermatology and Immune-Mediated Skin Disease
Research in skin and connective tissue diseases at this site includes studies in moderate to severe plaque psoriasis, atopic dermatitis, prurigo nodularis, vitiligo, alopecia areata, and hidradenitis suppurativa. The trials are mainly aimed at testing new therapies and improving symptom control, especially for inflammatory and autoimmune skin conditions.
- Assessing new options for plaque psoriasis and atopic dermatitis
- Evaluating treatments for itch and skin lesions in prurigo nodularis
- Studying therapies for vitiligo and alopecia areata in younger and adult patients
This dermatology portfolio highlights a broad effort to find more effective and better-tolerated approaches for chronic skin diseases.
Psychiatry and Cognitive Health
Clinical trials in mental disorders and related brain health conditions include major depressive disorder and mild cognitive impairment due to Alzheimer’s disease, as well as Alzheimer’s disease dementia. The research is centered on evaluating adjunctive treatments for depression and exploring ways to improve symptoms and cognitive outcomes in early neurodegenerative disease.
- Testing add-on therapies for major depressive disorder
- Exploring potential symptom improvement in mild cognitive impairment and early Alzheimer’s disease
- Assessing long-term safety and patient tolerability of new psychiatric and cognitive treatments
These studies show an interest in both emotional well-being and the early stages of cognitive decline, with a focus on practical treatment benefit.
Cardiovascular and Metabolic Research
The site also conducts trials in cardiovascular diseases and nutritional and metabolic diseases, including heart failure with preserved or mildly reduced ejection fraction, broader cardiovascular disease, and overweight and obesity. The main purpose of this research is to reduce cardiovascular risk, support weight loss, and improve outcomes in patients with inflammation-related heart disease and metabolic imbalance.
- Studying therapies for heart failure and cardiovascular inflammation
- Evaluating treatments to reduce major adverse cardiovascular events
- Investigating weight-management approaches for overweight and obesity
At this research site, cardiovascular and metabolic studies are aimed at lowering long-term health risks and improving everyday disease management.
Autoimmune and Inflammatory Disease Research
Across several therapeutic areas, Care Clinic Sp. z o.o. is involved in studies of immune system diseases that affect the nervous system, skin, muscles, and other organs. This includes research in myasthenia gravis and other autoimmune conditions, with a focus on understanding treatment response, safety, and the broader effects of immune-targeted therapies.
- Evaluating immune-focused treatments across multiple autoimmune conditions
- Studying safety and pharmacokinetics of therapies used in autoimmune diseases
- Supporting development of more precise approaches for chronic inflammatory illness
This area adds to the site’s broader profile as a center for research on long-term immune-mediated disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Incyte Corp.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Care Clinic Sp. z o.o.
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of JNJ-77242113 in Participants With Moderate to Severe Plaque Psoriasis Compared to Deucravacitinib or Placebo | Janssen Cilag International | Phase III | Not Yet Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 3 | Unknown | 2018-07-25 | 2026-06-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.